<DOC>
	<DOCNO>NCT02962388</DOCNO>
	<brief_summary>Prospective national multicenter randomize open label phase IIb RUXBETA trial .</brief_summary>
	<brief_title>The Ruxolitinib Versus Best Available Therapy Trial Patients With High Risk ET Second Line</brief_title>
	<detailed_description>A randomized , open label , multicenter phase IIb study evaluate efficacy safety Ruxolitinib versus best available therapy patient high risk essential thrombocythemia , resistant intolerant hydroxyurea .</detailed_description>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Target Population Men woman , age equal18 year le 75 year . Confirmed diagnosis Essential Thrombocythemia least 6 month , accord 2008 WHO criterion , highrisk status . Patients must treatment history ET meet definition resistance intolerance hydroxyurea therapy accord ELN criterion follow : Platelets 600.0109/L 3 month ( 12 week ) treatment dose 2g/day . Platelets 400.0 109/L WBC less 2.5109/L , whatever dose HU . Platelets 400.0 109/L Hb less 10g/dl whatever dose HU . Leg ulcer unacceptable mucocutaneous toxicity . HUrelated fever . ECOG Performance Status ( ECOG PS ) less equal 2 screen baseline . Adequate Organ Function : Direct bilirubin le 2.0 time institutional Upper Limit Normal ( ULN ) . Hepatic enzyme ( AST , ALT ) less equal 2.5 time institutional ULN . Adequate renal function screen demonstrate MDRDeGFR 30 mL/min/1.73m2 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy study . A male subject father potential must use adequate method contraception avoid conception study minimize risk pregnancy . For female male , restriction apply 24 hour last dose study drug . Women childbearing potential must negative serum ( betahuman chorionic gonadotropin hCG pregnancy test Screening . Signed Written Informed Consent . Health insurance coverage . Patients thrombocytosis relate another MPN ET Patients previously treat JAK2 inhibitor , Anagrelide Interferonalpha prior history therapy Hydroxyurea Contraindication Ruxolitinib , Anagrelide Interferonalpha ( eligible anagrelide ) , hypersensitivity excipient Medical history concurrent disease : Clinically significant cardiac disease ( NYHA Class III IV ) . Chronic hepatocellular disease . Subjects impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption Ruxolitinib Subjects clinically significant bacterial , fungal , parasitic viral infection require therapy : Subjects acute bacterial infection require antibiotic use delay screening/enrolment course antibiotic therapy complete . Subjects active hepatitis A , B C HIV positivity screen . Subjects diagnose primary immunodeficiency syndrome XLinked gammaglobulinemia common variable immune deficiency . Subject medical history tuberculosis History progressive multifocal leucoencephalopathy ( PML ) . Other malignant disease last 5 year prior inclusion except treated cervical intraepithelial neoplasia , basal cell carcinoma skin , squamous cell carcinoma skin , evidence recurrence past 3 year . History significant bleed disorder relate ET . Diagnosed congenital bleeding disorder , Diagnosed acquire bleed disorder within one year ( e.g . acquire antifactor VIII antibody ) , Ongoing recent ( 3 month ) significant gastrointestinal bleeding . Subjects uncontrolled undercurrent illness concurrent condition , investigator 's opinion , would jeopardize safety subject compliance protocol . Subjects treat concurrently potent systemic inhibitor CYP3A4 time screen . Subjects treat concurrently prohibit medication . Women pregnant breastfeeding eligible study . Inability freely provide consent judiciary administrative condition . Ongoing participation another clinical investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>